Tabrecta
Malignant Neoplasms
Treatment
1 Active Study for Tabrecta
Treatment for
Malignant Neoplasms
What is Tabrecta
Capmatinib
The Generic name of this drug
Treatment Summary
Capmatinib is a medication used to treat non-small cell lung cancer (NSCLC) in patients whose tumors have abnormal c-Met activity. This can be caused by mutations, amplifications, or overexpression of the c-Met gene. Capmatinib is sold under the brand name Tabrecta and was granted accelerated approval by the FDA in 2020. To use this medication, a doctor must first confirm the presence of the mutation using an FDA-approved test. The approval of this drug is conditional on further studies confirming its benefit.
Tabrecta
is the brand name
Tabrecta Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tabrecta
Capmatinib
2020
2
Effectiveness
How Tabrecta Affects Patients
Capmatinib helps to reduce the activity of c-Met, a type of protein found in certain cancers. After taking capmatinib, patients may become more sensitive to sunlight and should use sunscreen and protective clothing to reduce exposure to UV radiation. In some cases, taking capmatinib may cause lung disease, which can be fatal. If a patient experiences signs or symptoms of lung disease such as a cough, difficulty breathing, or fever, the capmatinib medication should be stopped and not restarted if no other cause can be found.
How Tabrecta works in the body
Capmatinib helps stop the spread of certain cancers, such as non-small cell lung cancer (NSCLC). It works by preventing a protein called c-Met from becoming overactive. This protein often has mutations in people with cancer, which can cause it to be overactive. Capmatinib blocks the action of this protein, preventing it from telling cells to grow and spread.
When to interrupt dosage
The portion of Tabrecta is reliant upon the determined condition. The dose can be found in the following table, contingent upon the technique of administration (e.g. Oral or Tablet).
Condition
Dosage
Administration
Malignant Neoplasms
, 200.0 mg, 150.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet
Warnings
Tabrecta Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Capmatinib may interact with Pulse Frequency
There are 20 known major drug interactions with Tabrecta.
Common Tabrecta Drug Interactions
Drug Name
Risk Level
Description
Ozanimod
Major
Capmatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Rimegepant
Major
The serum concentration of Rimegepant can be increased when it is combined with Capmatinib.
Silodosin
Major
The excretion of Silodosin can be decreased when combined with Capmatinib.
Tepotinib
Major
The serum concentration of Tepotinib can be increased when it is combined with Capmatinib.
Cephalexin
Minor
The excretion of Cephalexin can be decreased when combined with Capmatinib.
Tabrecta Toxicity & Overdose Risk
There is not much information available on the effects of overdosing on capmatinib. Animal studies have shown that capmatinib could have harmful effects on unborn babies, so both men and women taking this drug should use contraception during therapy and for one week after stopping treatment.
Tabrecta Novel Uses: Which Conditions Have a Clinical Trial Featuring Tabrecta?
Currently, 9 research studies are in progress to assess Tabrecta's ability to combat Malignant Neoplasms.
Condition
Clinical Trials
Trial Phases
Malignant Neoplasms
3 Actively Recruiting
Phase 1, Phase 2
Patient Q&A Section about tabrecta
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How do you take capmatinib?
"Capmatinib is a tablet that is taken by mouth, typically twice a day with or without food. It is important to take capmatinib at the same time each day and to follow the directions on the prescription label carefully. If there is something that is not understood, it is important to ask the doctor or pharmacist for an explanation."
Answered by AI
How much does capmatinib cost?
"Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209482s300lbl.pdf The drug cost for oral capmatinib is $17,950 per 28-day supply.23 This information comes from the RED BOOK; 2019; which can be found at the following URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209482s300lbl.pdf"
Answered by AI
When was Tabrecta FDA approved?
"The FDA has approved the use of the drug capmatinib for the treatment of metastatic non-small cell lung cancer in adults who have a specific genetic mutation."
Answered by AI
What does Tabrecta do?
"This medication is used to treat non-small cell lung cancer (NSCLC). Capmatinib works by inhibiting the growth of cancer cells."
Answered by AI